Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL8450325 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL28975729 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL104833 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL29189684 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL28408970 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL11883861 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL23581849 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL742814 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL467211 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT | |
| Phosphoric Acid SCHEMBL11565845 | 1.00 | SLC34A1 (0.42) | SLC34A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 837 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691459-A1 | COMBINATION FORMULATION COMPRISING SACUBITRIL-VALSARTAN AND SGLT-2 INHIBITOR HAVING IMPROVED STABILITY AND DISSOLUTION RATE | Hanmi Pharm. Co., Ltd. (KR) | 2026-02-11 | — | — | EP | claimed |
| US-20260014404-A1 | LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME | PERIMETER SOLUTIONS, LP (US) | 2026-01-15 | — | — | US | claimed |
| CN-120117743-A | Aerobic granular sludge culture method based on in-situ biomineralization | 湖南大学 | 2025-06-10 | — | — | CN | claimed |
| EP-2588154-B2 | COMPOSITION COMPRISING CALCIUM PHOSPHATE, SULFATE POWDERS OR DMB USED IN THE TREATMENT OF DEGENERATIVE BONE CONDITIONS | AGNOVOS HEALTHCARE LLC (US) | 2025-04-02 | — | — | EP | claimed |
| US-12116274-B2 | Method for preparing octacalcium phosphate and octacalcium phosphate prepared thereby | HUDENS BIO CO., LTD. (KR) | 2024-10-15 | — | — | US | claimed |
| WO-2024210557-A1 | COMBINATION FORMULATION COMPRISING SACUBITRIL-VALSARTAN AND SGLT-2 INHIBITOR HAVING IMPROVED STABILITY AND DISSOLUTION RATE | 한미약품 주식회사 | 2024-10-10 | — | — | WO | claimed |
| CN-118022050-A | Bone cement for nail channel reinforcement | 北京纳通医学研究院有限公司 | 2024-05-14 | — | — | CN | claimed |
| US-20230321046-A1 | PHARMACEUTICAL COMPOSITION OF SINGLE DOSAGE FORM FOR TREATING OR PREVENTING HYPERTENSION AND HYPERLIPIDEMIA | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2023-10-12 | — | — | US | claimed |
| CN-111247093-B | Method for preparing octacalcium phosphate and octacalcium phosphate prepared thereby | 株式会社秀顿斯生物 | 2023-08-29 | — | — | CN | claimed |
| EP-3887110-B1 | A METHOD OF PRODUCING CERAMICS-BASED COMPOSITE | MEDICAL INVENTI S A (PL) | 2023-08-23 | — | — | EP | claimed |
| WO-2005016616-A1 | METHODS FOR PREPARING MEDICAL IMPLANTS FROM CALCIUM PHOSPHATE CEMENT AND MEDICAL IMPLANTS | CALCITEC, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| US-20050029701-A1 | Method for making a molded calcium phosphate article | CANA LAB CORPORATION (TW) | 2005-02-10 | — | — | US | claimed |
| WO-2004003101-A1 | SYSTEM AND METHOD FOR REMOVING PARTICLES FROM A WELL BORE | HALLIBURTON ENERGY SERVICES, INC. (US) | 2004-01-08 | — | — | WO | claimed |
| US-20040000434-A1 | System and method for removing particles from a well bore penetrating a possible producing formation | HALLIBURTON ENERGY SERVICES, INC. | 2004-01-01 | — | — | US | claimed |
| US-20030216777-A1 | Method of enhancing healing of interfacial gap between bone and tendon or ligament | CALCITEC, INC. | 2003-11-20 | — | — | US | claimed |
| US-6648960-B1 | Heat treatment without using additives or sacrificing strength | CANA LAB CORPORATION (TW) | 2003-11-18 | — | — | US | claimed |
| CN-1403069-A | Process for producing slurry from calcium cementing agent | JINHUI CHEN (US) | 2003-03-19 | — | — | CN | claimed |
| CN-1378464-A | Brushite hydraulic cement stabilized with magnesium salts | H C ROBERT MATHYS STIFTUNG (CH) | 2002-11-06 | — | — | CN | claimed |
| CN-1334745-A | Implant comprising calcium-containing cement and hydrophobic liquid | H C ROBERT MATHYS STIFTUNG (CH) | 2002-02-06 | — | — | CN | claimed |
| WO-1995027518-A1 | BONE REGENERATION | PLASMA BIOTAL LIMITED (GB) | 1995-10-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014404-A1 | LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME | SLC6A12, SLC11A2, KCNN1 | SLC34A1 31/4885LMNA 4243/4885MAPT 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.